Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type Journal Article
PMID (40196870)
Authors Nakazawa T, Tsuzuki H, Kawase T, Mori M, Yoshida T
Title Anti-Tumor Effects of Gilteritinib on FLT3 Mutations: Insights into Resistance Mechanisms in Ba/F3 Cell Models.
URL
Abstract Text The efficacy of Fms-like tyrosine kinase 3 (FLT3) inhibitors has been well established against acute myeloid leukemia (AML) with FLT3 internal tandem duplication (FLT3-ITD) mutations. However, comparative data on the available inhibitors are limited, and drug resistance remains a major concern.This study examined the inhibitory effects of gilteritinib, quizartinib and midostaurin on Ba/F3 cells with FLT3-ITD mutations, or point mutations in the tyrosine kinase domain (TKD-PM) or juxtamembrane domain (JMD-PM), both in vitro and in vivo. Quizartinib and midostaurin were selected as comparators due to their clinical relevance in the AML setting and differing mechanisms of action.Gilteritinib showed similar or superior growth inhibition against the majority of FLT3-TKD-PM or FLT3-JMD-PM cells compared to FLT3-ITD-mutant cells. In contrast, the inhibitory effects of quizartinib were reduced on cells with most types of FLT3-TKD-PM, and the inhibitory effects of midostaurin were attenuated on cells with FLT3-TKD-PM N676K. Gilteritinib also effectively suppressed FLT3 autophosphorylation and phosphorylation of signal transducer and activator of transcription 5 (STAT5), AKT and extracellular signal-regulated kinase (ERK) in FLT3-TKD-PM cells, while quizartinib showed a reduced inhibitory effect on FLT3 autophosphorylation and phosphorylation of downstream signaling molecules in FLT3-TKD-PM cells. In mice xenografted with Ba/F3 cells expressing FLT3-ITD mutations or FLT3-TKD-PM, gilteritinib showed a potent antitumor effect, whereas the antitumor effect of quizartinib was significantly diminished in the FLT3-TKD-PM xenograft model.These findings highlight the potent efficacy of gilteritinib against a wide range of FLT3 mutations, including TKD-PM and JMD-PM, as well as those associated with resistance to quizartinib or midostaurin. This comparative analysis underscores the need for tailored therapeutic strategies in AML treatment, emphasizing the clinical significance of gilteritinib in overcoming drug resistance.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
FLT3 D593del deletion unknown FLT3 D593del results in the deletion of an amino acid in the juxtamembrane domain of the Flt3 protein at amino acid 593 (PMID: 14759363). D593del has been identified in the scientific literature (PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025).
FLT3 D835delinsLK indel unknown FLT3 D835delinsLK results in the deletion of aspartic acid (D) at amino acid 835 in the protein kinase domain of the Flt3 protein, combined with the insertion of a leucine (L) and a lysine (K) at the same site (UniProt.org). D835delinsLK has been identified in the scientific literature (PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025).
FLT3 I836delinsLD indel unknown FLT3 I836delinsLD results in the deletion of isoleucine (I) at amino acid 836 in the protein kinase domain of the Flt3 protein, combined with the insertion of a leucine (L) and an aspartic acid (D) at the same site (UniProt.org). I836delinsLD has been identified in the scientific literature (PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025).
FLT3 K663R missense unknown FLT3 K663R lies within the protein kinase domain of the Flt3 protein (UniProt.org). K663R has been identified in the scientific literature (PMID: 39080258, PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Sep 2025).
FLT3 R845S missense unknown FLT3 R845S lies within the activation loop of the protein kinase domain of the Flt3 protein (PMID: 25837374). R845S has been identified in the scientific literature (PMID: 32040554, PMID: 40196870), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Aug 2025).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 F594L hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F594L in culture (PMID: 40196870). 40196870
FLT3 D835A hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835A in culture (PMID: 40196870). 40196870
FLT3 K663R hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870). 40196870
FLT3 Y572C hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 Y572C in culture (PMID: 40196870). 40196870
FLT3 I836delinsLD hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836delinsLD in culture (PMID: 40196870). 40196870
FLT3 F590_Y591delinsGD hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870). 40196870
FLT3 N841I hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 N841I in culture (PMID: 40196870). 40196870
FLT3 F590_D593delinsLY hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F590_D593delinsLY in culture (PMID: 40196870). 40196870
FLT3 D835V hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835V in culture (PMID: 40196870). 40196870
FLT3 N841Y hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870). 40196870
FLT3 Y842C hematologic cancer resistant Quizartinib Preclinical Actionable In a preclinical study, cells expressing FLT3 Y842C were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). 40196870
FLT3 D835E hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870). 40196870
FLT3 R845S hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 R845S in culture (PMID: 40196870). 40196870
FLT3 V592G hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V592G in culture (PMID: 40196870). 40196870
FLT3 I867S hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I867S in culture (PMID: 40196870). 40196870
FLT3 F590_D593delinsLY hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F590_D593delinsLY in culture (PMID: 40196870). 40196870
FLT3 I836S hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836S in culture (PMID: 40196870). 40196870
FLT3 D835del hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835del in culture (PMID: 40196870). 40196870
FLT3 E598_Y599del hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 E598_Y599del in culture (PMID: 40196870). 40196870
FLT3 R834Q hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 R834Q in culture (PMID: 40196870). 40196870
FLT3 S840_N841insGS hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 S840_N841insGS in culture (PMID: 40196870). 40196870
FLT3 I836del hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836del in culture (PMID: 40196870). 40196870
FLT3 I836delinsLD hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836delinsLD in culture (PMID: 40196870). 40196870
FLT3 N676K hematologic cancer decreased response Midostaurin Preclinical - Cell culture Actionable In a preclinical study, cells expressing FLT3 N676K were less sensitive to Rydapt (midostaurin) compared to cells expressing a FLT3-ITD in culture (PMID: 40196870). 40196870
FLT3 I836delinsLD hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836delinsLD in culture (PMID: 40196870). 40196870
FLT3 V579A hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V579A in culture (PMID: 40196870). 40196870
FLT3 I836S hematologic cancer conflicting Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836S in culture (PMID: 40196870). 40196870
FLT3 R834Q hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 R834Q in culture (PMID: 40196870). 40196870
FLT3 Y842C hematologic cancer sensitive Gilteritinib Preclinical Actionable In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 Y842C in culture and inhibited growth in a transplant model (PMID: 40196870). 40196870
FLT3 I836T hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836T in culture (PMID: 40196870). 40196870
FLT3 D593del hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D593del in culture (PMID: 40196870). 40196870
FLT3 I836S hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836S in culture (PMID: 40196870). 40196870
FLT3 I836T hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836T in culture (PMID: 40196870). 40196870
FLT3 F590_D593delinsLY hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F590_D593delinsLY in culture (PMID: 40196870). 40196870
FLT3 D835delinsLK hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835delinsLK in culture (PMID: 40196870). 40196870
FLT3 D839G hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D839G in culture (PMID: 40196870). 40196870
FLT3 V592G hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V592G in culture (PMID: 40196870). 40196870
FLT3 D839G hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D839G in culture (PMID: 40196870). 40196870
FLT3 I836T hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I836T in culture (PMID: 40196870). 40196870
FLT3 K663Q hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870). 40196870
FLT3 I867S hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 I867S in culture (PMID: 40196870). 40196870
FLT3 N841I hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 N841I in culture (PMID: 40196870). 40196870
FLT3 K663R hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870). 40196870
FLT3 D835N hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835N in culture (PMID: 40196870). 40196870
FLT3 N841I hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 N841I in culture (PMID: 40196870). 40196870
FLT3 F590_Y591delinsGD hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870). 40196870
FLT3 D593del hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D593del in culture (PMID: 40196870). 40196870
FLT3 D835E hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870). 40196870
FLT3 N841Y hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870). 40196870
FLT3 N676K hematologic cancer resistant Quizartinib Preclinical Actionable In a preclinical study, cells expressing FLT3 N676K were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). 40196870
FLT3 D835G hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835G in culture (PMID: 40196870). 40196870
FLT3 V592A hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870). 40196870
FLT3 D835del hematologic cancer sensitive Gilteritinib Preclinical Actionable In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835del in culture and inhibited growth in a transplant model (PMID: 40196870). 40196870
FLT3 V592A hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870). 40196870
FLT3 V579A hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V579A in culture (PMID: 40196870). 40196870
FLT3 V592A hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 V592A in culture (PMID: 40196870). 40196870
FLT3 F590_Y591delinsGD hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F590_Y591delinsGD in culture (PMID: 40196870). 40196870
FLT3 K663Q hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870). 40196870
FLT3 Y572C hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 Y572C in culture (PMID: 40196870). 40196870
FLT3 D835V hematologic cancer sensitive Gilteritinib Preclinical Actionable In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835V in culture and inhibited growth in a transplant model (PMID: 40196870). 40196870
FLT3 S840_N841insGS hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 S840_N841insGS in culture (PMID: 40196870). 40196870
FLT3 V579A hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V579A in culture (PMID: 40196870). 40196870
FLT3 D835V hematologic cancer resistant Quizartinib Preclinical Actionable In a preclinical study, cells expressing FLT3 D835V were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). 40196870
FLT3 D835G hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835G in culture (PMID: 40196870). 40196870
FLT3 I867S hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I867S in culture (PMID: 40196870). 40196870
FLT3 E598_Y599del hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 E598_Y599del in culture (PMID: 40196870). 40196870
FLT3 K663R hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 K663R in culture (PMID: 40196870). 40196870
FLT3 D835E hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835E in culture (PMID: 40196870). 40196870
FLT3 V592G hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 V592G in culture (PMID: 40196870). 40196870
FLT3 Y842C hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 Y842C in culture (PMID: 40196870). 40196870
FLT3 D835G hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835G in culture (PMID: 40196870). 40196870
FLT3 F594L hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 F594L in culture (PMID: 40196870). 40196870
FLT3 R834Q hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 R834Q in culture (PMID: 40196870). 40196870
FLT3 D839G hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D839G in culture (PMID: 40196870). 40196870
FLT3 Y572C hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 Y572C in culture (PMID: 40196870). 40196870
FLT3 I836del hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 I836del in culture (PMID: 40196870). 40196870
FLT3 N676K hematologic cancer sensitive Gilteritinib Preclinical Actionable In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 N676K in culture and inhibited growth in a transplant model (PMID: 40196870). 40196870
FLT3 K663Q hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 K663Q in culture (PMID: 40196870). 40196870
FLT3 R845S hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 R845S in culture (PMID: 40196870). 40196870
FLT3 D835N hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 D835N in culture (PMID: 40196870). 40196870
FLT3 I836del hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 I836del in culture (PMID: 40196870). 40196870
FLT3 S840_N841insGS hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 S840_N841insGS in culture (PMID: 40196870). 40196870
FLT3 D835del hematologic cancer decreased response Quizartinib Preclinical Actionable In a preclinical study, cells expressing FLT3 D835del were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). 40196870
FLT3 F594L hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 F594L in culture (PMID: 40196870). 40196870
FLT3 D835A hematologic cancer conflicting Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D835A in culture (PMID: 40196870). 40196870
FLT3 N841Y hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 N841Y in culture (PMID: 40196870). 40196870
FLT3 D835N hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835N in culture (PMID: 40196870). 40196870
FLT3 D835delinsLK hematologic cancer decreased response Quizartinib Preclinical Actionable In a preclinical study, cells expressing FLT3 D835delinsLK were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). 40196870
FLT3 D593del hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 D593del in culture (PMID: 40196870). 40196870
FLT3 D835delinsLK hematologic cancer sensitive Gilteritinib Preclinical Actionable In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835delinsLK in culture and inhibited growth in a transplant model (PMID: 40196870). 40196870
FLT3 D835A hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835A in culture (PMID: 40196870). 40196870
FLT3 E598_Y599del hematologic cancer sensitive Quizartinib Preclinical - Cell culture Actionable In a preclinical study, Vanflyta (quizartinib) treatment decreased viability in a cell line expressing FLT3 E598_Y599del in culture (PMID: 40196870). 40196870
FLT3 R845S hematologic cancer sensitive Gilteritinib Preclinical - Cell culture Actionable In a preclinical study, Xospata (gilteritinib) treatment decreased viability in a cell line expressing FLT3 R845S in culture (PMID: 40196870). 40196870